Benefit of expedited regulatory approval for oncology drugs eliminated by slow reimbursement reviews and price negotiations
Benefit of expedited regulatory approval for oncology drugs eliminated by slow reimbursement reviews and price negotiations Nigel S B Rawson and David J Stewart ABSTRACT Summary: In an examination of 92 oncology drugs that received regulatory approval
Authors
- Nigel S. B. Rawson (ORCID: https://orcid.org/0000-0001-6843-4890)
- David J. Stewart (ORCID: https://orcid.org/0000-0002-0184-7946)
Institutions
- Ottawa Hospital (CA)
Publication Details
- Journal
- Canadian Health Policy
- Published
- 2024-08-20
- DOI
- https://doi.org/10.54194/kjry1417
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00